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ABSTRACT 
RATIONALE: World Anti-doping Agency (WADA) encourages drug testing laboratories to 
develop screening methods that can detect as many doping substances as possible in urine. 
The use of full scan high-resolution acquisition (FS/HR) with GC/MS for the detection of 
known and unknown TMS derivatives of AAS provides anti-doping testing bodies with a 
new analytical tool. 
METHODS: The AAS extracted from urine samples by generic liquid-liquid extraction, 
after enzymatic hydrolysis, and trimethylsilyl (TMS) derivatization step. The extracted urine 
analysed by GC/Q-TOF and GC/Q-Orbitrap to compare the performance of both instruments 
for the detection of 46 AAS in human urine. The quantitation of endogenous anabolic 
steroids and the ability of the two analytical platforms to comply with the requirements for 
testing as part of the WADA Athlete Biological Passport (ABP) was also assessed. 
RESULTS: Data presented shows that the analytical performance is in compliance with the 
WADA specifications for both instruments. The LOD(s) for both instruments are well below 
the 50% MRPL sensitivity level. The mass errors in the current study for the GC/Q-Orbitrap 
platform are lower compared to the respective of the GC/Q-TOF. 
CONCLUSIONS: The data presented herein proved that both molecular profiling platforms 
can be used for antidoping screening. The mass accuracies are excellent in both instruments, 







The World Anti-doping Agency (WADA) Prohibited List [1] comprises prohibited classes of 
drugs with pharmacological activity. The small molecules included on the list are detected 
using mass spectrometry (MS) coupled with either liquid chromatography (LC) or gas 
chromatography (GC). The criteria used to select the method of analysis are determined 
mainly by the sensitivity, specificity and matrix effects that fulfil the specifications of the 
WADA International Standard for Laboratories (ISL) [2] and the WADA Minimum Required 
Performance Levels (MRPL) technical document TD MRPL [3]. The molecules analysed by 
GC/MS are usually those with chemical structures that result in low ionization efficiency 
with LC/MS [4]. 
In the sports anti-doping field, GC/MS screening typically utilizes low-resolution GC triple 
quadrupole technology (GC/QQQ) [5]; however, a few methods have been published that 
utilize full-scan (FS) and high-resolution (HR) acquisition modes. In 2007, a time-of-flight 
(TOF) screening method was published [6] that could be used for the analysis of synthetic 
anabolic-androgenic steroids (AAS). However, the WADA specifications in 2007 were less 
demanding than the contemporary regulations. In another study, a limited screening method 
based on two-dimensional (2D) GC coupled to time-of-flight mass spectrometry was 
published that could be used for selected anabolic agents [7]. In another, more comprehensive 
study from the same research group, a screening method based on quadrupole-Orbitrap 
GC/MS was published for use in the detection of a large number of substances in urine, such 
as synthetic AAS, β-agonists, stimulants, narcotics, metabolic modulators and diuretics, that 
fulfilled the WADA sensitivity specifications [8]. Finally, in another recent study [9], a 
routine screening method that used GC/MS with a triple quadrupole instrument was adapted 
for use with a QTOF GC/MS instrument and subjected to full validation, in which the FS/HR 
MS acquisition mode was applied to detect and quantify exogenous and endogenous steroids 
[10]. 
However, FS/HR GC/MS technologies are more widely in other analytical fields than in anti-
doping analysis. A recent review that focused on the use of GC/MS with TOF mass analysers 
describes their use for the analysis of a large number of organic contaminants and residues 
present at trace levels for environmental, food safety and biological applications [11]. A 
recent example of the use of FS/HR GC/MS in the food analysis field combined atmospheric 
pressure chemical ionization (APCI) with the use of a QTOF mass analyser for the analysis 
of the volatile components of olive oil [12]. 
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The use of GC/MS coupled with TOF and QTOF mass analyser technologies and two-
dimensional GC (GC×GC) has been recently reviewed [13]. The author observed that the 
popularity of GC×GC is increasing and the number of components that can be simultaneously 
detected is limited by characteristics of the MS system such as the dynamic range, resolution 
and scanning speed, and eluting GC×GC peaks. Moreover, several recent applications of this 
method to toxicology, clinical chemistry, food and environmental analysis has been recently 
reviewed [13].. In toxicology, the volatile organic compounds (VOCs) produced during the 
early stages of bodily decomposition can be detected using thermal desorption coupled to 
GC/GC/TOF MS, which could be used for a wide variety of forensic or epidemiologic 
purposes, such as during natural catastrophes with large numbers of collapsed buildings [14]. 
In clinical chemistry, the quantitative analysis of organic acids in urine has been performed 
using GC/GC/TOF MS to determine abnormal patterns that can indicate the presence of 
inherited disorders of organic acid metabolism [15]. In food analysis, GC/GC TOF MS has 
been applied to the investigation of dioxin-like micropollutants in animal-derived food 
matrices [16]. In environmental analysis, the profiling of short- and medium-chain 
chlorinated paraffins in sediment and fish samples using GC/GC/TOF MS with negative 
ionization has been demonstrated [17]. 
Along with molecular profiling using TOF mass analysers, the use of the GC/Q-Orbitrap has 
been recently developed. The use of HR/FS GC/Orbitrap MS with electron  ionization was 
evaluated for use in pesticide residue analysis in fruit and vegetables [18]. In food analysis, 
GC and LC coupled to Orbitrap MS has been applied to the identification of substances that 
have migrated from nano-films in food packaging [19]. 
The advantages of the HR/FS-MS method for anti-doping screening analysis have been 
described by Friedmann et al [20]. The HR mass filter results in enhanced specificity and 
sensitivity and the reduction of background noise, and full scan acquisition allows for the 
detection of a virtually unlimited number of analytes, which can be identified by reprocessing 
of the acquired data files. Using FS/HR-GC/MS for the identification of designer drugs 
[21,22], and as well as novel metabolites that allow for the prolonged detection of substances 
with “zero tolerance,” such as AAS [23,24] has been demonstrated. 
Synthetic AAS are prohibited [1] and present a challenge [3] for anti-doping screening 
laboratories, since their presence should still be detected at low concentrations for a long 
period of time after administration of banned substances. Moreover, endogenous AAS [10], 
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such as testosterone and prohormones, are administered exogenously to enhance endogenous 
AAS levels. Because there is no difference in the mass spectra produced by exogenously 
administered AAS and their endogenously produced counterparts, an indirect methodology 
based on the ratio of AAS metabolites is currently used to identify possible abuse of 
substances. To alleviate these challenges, the WADA introduced the steroid profile and 
WADA Steroidal Athlete Biological Passport (ABP), which contains the quantified results of 
endogenous AAS screening analyses conducted during the career of the professional athlete 
for the following  parameters: Testosterone (T), Epitestosterone (E), Androsterone (A), 
Etiocholanolone (Etio), 5α-androstan-3α,17β-diol (5αadiol), 5β-androstan-3α,17β-diol 
(5βadiol) and the following ratios: T/E, A/Etio, 5αadiol/5βadiol, A/T, 5αadiol /E, for each 
analyzed sample [10]. The concentrations of the markers, in addition to the ratios of AAS 
metabolites, are also used in the identification of possible abuse [25]. 
The goal of this study is the comparison of two HR/FS-GC/MS molecular screening 
technologies, which are based on the Agilent GC/Q-TOF and the Thermo GC/Q-Orbitrap, 
using the same sample aliquots and the same GC parameters and conditions for both 
instruments. Both the QTOF and Orbitrap mass analysers allow for high mass resolution, but 
the Orbitrap mass analyser generally produces higher-resolution spectra at a lower scanning 
speed and higher dynamic range, depending on the applied acquisition parameters, due its 
increased ion trapping ability. We present an analytical platform comparison study that uses 
these two MS analysers for the detection of anabolic steroids and that includes the qualitative 
screening of synthetic AAS, the quantitative profiling of endogenous AAS and the 
reprocessing of the electronic data files for preventive analysis. In this article, the 
performance of the GC/QTOF and GC/Q-Orbitrap in the detection and quantitation of 
exogenous and endogenous AAS in the same urine samples is compared. The analysis 
comprises a limited number of analytes, including representative exogenous AAS and all of 
the endogenous AAS that are present in the steroidal ABP. 
 
EXPERIMENTAL 
Chemicals and Reagents 
Sodium hydrogen carbonate and diethyl ether were supplied by Merck (Darmstadt, 
Germany). Methanol (HPLC grade), 2-propanethiol, di-potassium hydrogen phosphate, 
potassium dihydrogen phosphate, ammonium iodide and sodium bicarbonate were supplied 
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by Sigma Aldrich (Darmstadt, Germany). β-Glucuronidase derived from Escherichia coli (E. 
coli) was supplied by Roche (Mannheim, Germany). MSTFA (N-methyl-N-(trimethylsilyl) 
trifluoroacetamide) was supplied by Carl Bucher (Waldstetten, Germany). 
Reference Materials  
The following internal standards (ISTD) were purchased from LGC (Wesel, Germany): D5-
etiocholanolone (d5 Etio), D4-androsterone glucuronide (d4A Glu), D3-testosterone (d3T), 
D3-epitestosterone (d3E), and D5-5β-androstane-3α-17β-diol (D5-5βDiol). The remaining 
reference standard materials were purchased from LGC (Wesel, Germany), TRC (Toronto, 
Canada), Sigma Aldrich (Darmstadt, Germany), Steraloids (Newport, USA), and Cerilliant 
(Round Rock, USA). Standard stock solutions of the analytes were individually prepared in 
methanol. For validation purposes, standard working solutions containing the analytes were 
prepared in methanol by subsequent dilution of the stock solutions. The analytes from the 
endogenous steroid profile were diluted in a different working solution. All of the solutions 
were stored at -20°C in amber vials. 
Sample preparation 
The sample preparation was described in detail for a previous study [9]. In brief, it included a 
liquid-liquid extraction with diethyl ether at pH 9-10 and a desalting step, which is an 
approach that is commonly used to extract doping substances from the urine matrix. A clean 
extract was obtained after the separation of the organic layer from the aqueous phase 
following centrifugation and the cooling of the extraction tubes in an ethanol basin at -80°C. 
Prior to the extraction step, deconjugation of the Phase II steroid glucuronide conjugates was 
performed by enzymatic hydrolysis using the E. coli-derived β-glucuronidase as indicated in 
[10]. The final step of the sample preparation was the derivatization of the extracts with 
trimethyl silane (TMS), which was performed in a mixture of MSTFA, ammonium iodide 
and propanethiol; in these conditions, both the hydroxyl and the keto steroidal groups were 
derivatized [26] by the TMS group. 
 
Instruments and analytical conditions 
GC/EI/quadrupole time-of-flight analysis conditions 
The GC/MS system used in the current study was an GC 7890 coupled with a 7200 Q-TOF 
mass spectrometer (G3850-64101; Agilent, Delaware, USA) equipped with a BPX5 5% 
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phenyl polysilphenylene-siloxane capillary column (30 m length, 0.25 mm ID, 0.1 µm film 
thickness; SGE, Victoria, Australia) and a back-flush system. The combination of the 
quadrupole device with the TOF MS analyser provides the capability to conduct MS/MS 
experiments. Helium was used as a carrier gas at a constant flow of 1.1 mL/min. The 
injection port temperature was set to 280 °C, and the injection volume was set to 2 µL with a 
split ratio of 20:1. The oven temperature was initially set at 160 °C, increased at 10 °C/min to 
200 °C, then increased at 2 °C/min to 220 °C, followed by an increase at 6 °C/min to 292 °C 
and 50 °C/min to 310 °C, where it was held for 3 min. The analysis run time was 29.36 
minutes. The interface temperature was set to 280 °C and the ion source was set to 250 °C. 
Electron ionization (EI) of the compound ionization was performed using 70 eV of electron 
energy. A 2 GHz extended dynamic range (EDR) acquisition mode was used for the TOF 
data acquisition. The acquisition rate was 5 spectra per sec (200 msec per spectrum), and the 
number of transients per spectrum was set to 2718. GC/Q-TOF has the capacity to acquire 
MS data in FS/HR mode with a mass accuracy of <5 ppm mass error in EI mode, depending 
on the concentration of the analytes. The applied MS range (m/z 80-670) allows for the 
measurement of small molecules typically analysed with GC/QTOF. Automated mass 
calibration was performed after every three injections using perfluorotributylamine (PFTBA, 
Agilent).  
 
GC-EI-quadrupole Orbitrap analysis conditions 
The second GC/MS system used in the current study was a GC/Q-Orbitrap (Q Exactive GC, 
Thermo Scientific, Bremen, Germany), equipped with an SGE BPX5 column (30 m length, 
0.25 mm ID, 0.1 µm film thickness). This system consisted of a TriPlus RSH autosampler, a 
TRACE 1310 GC with a hot split/splitless injector, an EI source, and a hybrid quadrupole 
Orbitrap (Q Exactive) mass spectrometer with HCD (higher energy collusion-induced 
dissociation). The sample introduction was performed using the TriPlus RSH autosampler. 
Helium was used as carrier gas with a constant flow set at 1.1 mL/min. The same analysis 
conditions for the GC parameters described in the previous section (GC/EI/Quadrupole time-
of-flight analysis conditions) was used. EI at 70 eV was used for the compound ionization 
with a source temperature set at 250 ℃. Full scan acquisition mode was applied with a mass 
range of m/z 80-670 with 1 µsec scans, a resolving power of 60,000 at m/z 200 and an AGC 
target set at 3·106. The mass calibration procedure was performed before each acquisition 
batch using PFTBA. The internal mass calibration during the measurement was conducted 
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using three different background ions that originated from the column bleed (m/z 207.03236/ 
C2H15O3Si3
+, 281.05115/ C7H21O4Si4
+ and 355.06994/ C9H27O5Si5
+) with a search window of 
± 2 ppm. 
 
Qualitative analysis 
The validation of the screening method on both instruments was performed according to ISL 
guidelines [2]. In this procedure the following parameters were evaluated and validated: the 
identification capability, the specificity and the limit of detection. To assess the retention time 
for each compound, a mixture of standards at a high concentration (10-fold of the MRPL) 
was injected into both instruments. The evaluation of the compound identification capability 
based on the retention time was performed using 10 different blank urine samples that were 
spiked with a standard mixture of 46 synthetic anabolic steroids at concentrations of 50% of 
the MRPL [3]. To evaluate the specificity of the developed methods, 10 blank urine samples 
were analysed in order to demonstrate the absence of any interference. The limit of detection 
(LOD) was determined by spiking the urine samples with a mixture of standards at 10%, 
25%, 50% and 100% of the MRPL. The LOD is the lowest concentration at which a 
compound can be detected with sufficient data points and the elimination of background 
interference. The validation results showed that the analytical methods that were used in this 




The method used for quantitative compound profiling was validated on both instruments. The 
validation process was carried out over a period of three days. The linearity, precision, 
accuracy and combined measurement uncertainty were evaluated. The calibration curves for 
quantification purposes were generated from stripped urine samples, which were blank urine 
samples collected from female children and depleted of endogenous steroids using C18 SPE 
extraction and collection of the eluent to avoid any interference with the endogenous steroids 
in the urine matrix, that were spiked with the standards. The calibration curves were obtained 
by measuring the levels of endogenous AAS included in the steroid profile of the ABP at 
seven different concentrations of standards; concentrations of 2-400 ng/mL were used for T 
and E, 100-8000 ng/mL for A and Etio, and 4-800 ng/mL for 5αadiol and 5βadiol. The ratio 
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of the peak height (m/z) that was obtained for the analyte to the peak height of the internal 
standard was calculated and plotted against the concentration of the added analyte. Linearity 
was determined by using the weighed linear regression model (W=1/X, where X is the 
concentration of the analyte). The precision and accuracy of the method were determined 
using a level of spiked quality control (QC) samples that corresponded to level 5 of the 
calibration curve, which were prepared in four different aliquots. The analysis was performed 
using 4 replicates for each level for each day (n=4) over a period of three days (n=12). The 
intermediate precision was determined from the data obtained from the QC samples collected 
during the 3 days of the experiments. Both the intermediate precision and accuracy (% bias) 
that were calculated based on the QC samples were used to estimate the combined 
measurement uncertainty (MU) for each steroid according to the following equation: 
Combined 𝑀𝑈 = √𝑖𝑛𝑡𝑒𝑟𝑚𝑒𝑑𝑖𝑎𝑡𝑒 𝑝𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛2 + 𝐵𝑖𝑎𝑠2 
 
RESULTS AND DISCUSSION 
The current study was conducted using the same samples and chromatographic conditions in 
two different laboratories: Anti-Doping Lab Qatar (ADLQ) in Qatar (GC/QTOF) and 
RIKILT-Institute of Food Safety (GC/Q-Orbitrap) in the Netherlands. The same sample set 
was analysed on both analytical platforms within two weeks period in order to reduce 
possible variability due to sample stability. The methods applied herein were based on that of 
a previous study [9], with the exception of the GC/Q-Orbitrap MS method, which is 
described in the Materials and Methods section. The entire sample preparation procedure was 
conducted at ADLQ, where the aliquots were subsequently analysed using QTOF. 
Afterwards, the aliquots were safely sent to RIKILT at room temperature and reanalysed 
using the GC/Q-Orbitrap instrument with the same chromatographic conditions, including 
identical injection port liner, chromatographic column and temperature parameters. The only 
difference in the two chromatographic systems was the inclusion of a back-flush device 
installed on the QTOF instrument. In this study, representative AAS were selected for 
analysis. AAS are considered to be drugs with anabolic pharmacological activity that is 
highly beneficial for the enhancement of athletic performance, even long after administration. 
Consequently, AAS are required to be detected by anti-doping laboratories at the lowest 
possible concentrations, even below the values specified by WADA [3]. To this end, AAS 
were analysed at concentrations close to their limit of detection (LOD). The measured AAS 
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analytes included endogenous AAS that are part of the ABP SP, AAS analytes that are easily 
detected by GC analysis, as well as analytes that are problematic for GC analysis due to 
matrix interferences.  
The MS tuning and calibration procedures were applied to both instruments according to the 
manufacturers’ specifications. The full width at half maximum (FWHM) resolution was set to 
60,000 (specified at m/z 200) during the tuning procedure for the Q/Orbitrap and to 12,000 
(specified at m/z 272) for the QTOF. These conditions, in addition to the conditions described 
in the instruments and analytical conditions section, provided sufficient data points to identify 
and quantify the analyte peaks in the FS-HR-GC/MS data; there were 20-30 and 30-50 data 
points across the chromatographic peaks for the Q/Orbitrap and the QTOF data, respectively. 
For the GC/Q-Orbitrap, the mass accuracy reached 2 ppm error due to the use of lock mass 
recalibration with ions (m/z 207.03236, 281.05115, and 355.06994) that originated from the 
column bleed. The GC/QTOF method did not include a lock mass procedure during 
acquisition; however, the mass calibration procedure was repeated after three sample 
injections. 
 
Qualitative analysis results 
Table 1 summarizes the qualitative parameters used to validate the AAS screening conducted 
using both instruments. The GC/MS method provided sufficient data quality to discriminate 
between the MS signals derived from each of the investigated analytes using both 
instruments. Figure 1 shows the comparison of the mass accuracies for the molecular ions 
and other fragment ions produced by the analysed AAS from Table 1, which were spiked at 
2.5 ng/mL as a function of the m/z. Table 2 summarizes the reproducibility of the mass 
accuracy for the GC/QTOF and GC/Q-Orbitrap analyses of 10 different urine samples based 
on the base peaks of the selected AAS. Overall, the mass errors for the GC/Q-Orbitrap 
platform in the current study are lower than those for the GC/QTOF system.  
The identification capability parameters [2], which are based on the detectability of the AAS 
within the different urine matrices at 50% of the MRPL concentration [3], are shown in Table 
1. The LOD for each AAS is also shown in Table 1. 
Figure 2 shows the extracted ion chromatograms for the main fragment ions derived from the 
following AAS compounds: 1-testosterone, 5β-androst-1-ene-17β-ol-3-one (boldenone m1), 
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3'OH stanozolol, epimetendiol, bolasterone, 9α-fluoro-18-nor-17,17-dimethyl-4,13-diene-11β-
ol-3-one (flouxymesterone-18nor), 13β,17α-diethyl-5β-gonane-3α,17β-diol (norbolethone 
m2), 19-norandrosterone (nandrolone m1), oxymesterone and clenbuterol. An improvement 
in the detection of 3'OH stanozolol using GC/Q-Orbitrap was noted, which was due to the 
lower level of matrix interference it had compared to that of GC/QTOF. Moreover, 
clenbuterol was detected unambiguously using GC/Q-Orbitrap with the FS-HR mode at 0.1 
ng/ml; it was only possible to detect this compound in MS/MS mode using GC/QTOF [9]. 
The detection of other compounds, such as boldenone, bolasterone and 13β,17α-diethyl-5α-
gonane-3α17β-diol, was subject to interference using either instrument. 
 Generally, the chromatographic data obtained from routine screening using GC and LC/MS 
is independently evaluated by two analysts in order to identify suspicious ions that may be 
the result of a prohibited substances abuse. These suspicious signals activate specific 
confirmatory procedures that include testing of a new aliquot of the suspicious urine sample. 
A routine batch of samples analysed by GC/MS or LC/MS methods may generate tens of 
thousands of ion chromatograms that have to be reviewed one by one. Consequently, the 
quality and reproducibility of the ion chromatograms to be reviewed is important in reducing 
errors during the evaluation of doping tests. In an HR instrument, the mass accuracy of the 
ion chromatograms influences the quality of their evaluation. If the mass extraction window 
is too wide, then the matrix interference is enhanced; if it is too narrow, then there is an 
increased risk of not detecting a prohibited substance due to mass error. In the current study, 
the mass extraction windows were optimized and set to 20 ppm for GC/QTOF and 5 ppm for 
GC/Q-Orbitrap, and the same m/z values were used for the detection of the analytes. The 
Orbitrap method can be further optimized via the use of the chromatographic back-flush 
device and the inclusion of MS/MS acquisition, both of which were applied only to the 
GC/QTOF analysis in the current study. Both the GC/QTOF and the GC/Q-Orbitrap 
instruments were equipped with a quadrupole device that allowed for the acquisition of 
MS/MS. 
 
Quantitative analysis results 
The development of a new GC/MS anti-doping screening method that cannot measure 
endogenous AAS has no practical utility [10, 25]. Therefore, the current study included 
screening of the six endogenous AAS that are listed in Table 3 for both instruments. The data 
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presented in Table 3 demonstrates that the analytical performance of both instruments is in 
compliance with the WADA specifications [10]. It can be seen that the MU is less than 20% 
for A and Etio, 25% for 5αadiol and 5βadiol and less than 20% for T and E. The endogenous 
concentrations of androsterone and etiocholanolone may be high relative to those of the other 
AAS (e.g., 8 μg/mL), so to avoid detector saturation, the full scan MS mode was not used for   
QTOF, but instead the transition of m/z from 434.3031 to 419.2796 was retraced at lower 
abundances using the MS/MS data. The GC/Q-Orbitrap method was conducted in FS mode 
during testing of all of the steroids. It should be noted, however, that the Orbitrap platform is 
less prone to detector saturation than QTOF because the Orbitrap is an ion trapping 
instrument that can adapt to higher analyte concentrations by reducing the ion acquisition 
time via automatic gain control and, thereby, allow for the detection of a larger dynamic 
concentration range than QTOF. Overall, the data acquired from both instruments was in 
compliance with the specifications given in the technical document TD2016EAAS [10]. In 
another study, a comparison of steroid profile data obtained using GC/QTOF and GC/QQQ 
was previously made [9].  
 
Analysis of a proficiency test sample 
The analysis of a proficiency testing sample was also successfully conducted using both 
instruments. The sample was obtained from an individual to whom nandrolone was 
administered; the two main metabolites of nandrolone, 19-norandrosterone and 19-
noretiocholanolone, were detected. Figure 3 presents the FS-HR spectrum of 19-
norandrosterone obtained at a concentration of 6.2 ng/mL using both the GC/QTOF and 
GC/Q-Orbitrap platforms.  
 
CONCLUSIONS 
The goal of the current study was the comparison of the performance of the GC/QTOF and 
GC/Q-Orbitrap molecular profiling technologies during routine anti-doping screening and the 
assessment of the qualitative and quantitative analyses resulting from the use of both 
platforms. The data presented herein demonstrate that both molecular profiling platforms can 
be used for anti-doping screening. It was also shown that it is possible to combine FS-HR 
acquisition with MS/MS to enhance specificity in order to facilitate screening for AAS. The 
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LODs for both instruments were well below 50% of the MRPL sensitivity level. The 
identification criteria data shows that a limited number of compounds were not able to reach 
100% detectability in the various urine matrices. The mass accuracies were excellent for both 
instruments; however, the GC/Q-Orbitrap had superior mass accuracy due to its higher 
resolution. The superiority of the GC/Q-Orbitrap was also demonstrated by the lower matrix 
effects found in the urine samples in relation to the mass accuracies. Overall, both 
instruments proved to be sufficiently robust for routine anti-doping testing and analysis. The 
results of the reprocessing of the existing data files to identify substances that previously 
escaped detection in FS mode will be presented in a future report. 
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diol d5, ISTD 
C25H43D5O2Si2 14.15 246.2265 261.2499 
  
ISTD 
44 Androsterone  C25H46O2Si2 13.8 434.3031 329.2295 419.2796 EAAS 
45 Androsterone d4, ISTD C25H42D4O2Si2 13.5 438.3282 333.25463 423.3047 ISTD 




C25H41D3O2Si2 15.86 435.3063 420.2828   ISTD 
19 
 




C25H41D5O2Si2 13.78 439.3345 334.2609 424.3109 ISTD 
 Spiked concentration at 50% of the MRPL. 
EAAS: endogenous androgenic-anabolic steroids 









(ppm) STD max min 
Q-ToF 
5β-androst-1-ene-17β-ol-3-one 194.1121 3.15 2.96 9.27 0.00 
6-oxo- androstenedine 516.2906 7.62 3.73 13.17 2.32 
1α-methyl-5α-androstane-3α-ol-17-
one 433.2953 2.67 1.73 5.77 0.69 
17α-Ethyl-5β-estrane-3α,17β-diol 331.2458 5.30 5.72 15.09 0.30 
Q-Orbitrap 
5β-androst-1-ene-17β-ol-3-one 194.1121 0.40 0.23 0.52 0.00 
6-oxo- androstenedine 516.2906 1.01 0.09 1.16 0.97 
1α-methyl-5α-androstane-3α-ol-17-
one 433.2953 0.18 0.22 0.46 0.00 
17α-Ethyl-5β-estrane-3α,17β-diol 331.2458 1.81 0.48 2.72 1.21 
 
 































Androsterone (A) 100-8000 15.1 10.9 4.3 4.02 15.7 11.6 
Etiocholanolone 
(ETIO) 100-8000 9.1 5.7 6.2 4.3 11 7.2 
5α-Androstandiol 
(5αdiol) 4-800 5.8 6.5 0.8 4.7 5.9 7.7 
5β-Androstandiol 
(5βdiol) 4-800 5.1 6.1 1.9 5.3 5.5 8.1 
Testosterone (T) 2-400 9.1 17.2 1.2 1.1 9.2 17.2 
Epitestostrone (E) 2-400 8.4 2.1 9 1.5 12.3 2.6 
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Figure 2. 
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